Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis

Molecular Medicine Reports

Volumn 1, Issue 4, 2008, Pages 565-569

  Krzeslak, Anna ^a   Gaj, Zuzanna ^a   Pomorski, Lech ^b   Lipinska, Anna ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cytokeratin 19; Thyroid lesions; Western blot analysis

Indexed keywords

CYTOKERATIN 19;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CHILD; CONTROLLED STUDY; CYTOSOLIC FRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCHOOL CHILD; THYROID ADENOMA; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; WESTERN BLOTTING;

EID: 69249154668     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.4.565     Document Type: Article

References (28)

1. Coulombe PA and Omary MB: Hard and soft principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 14: 110-122, 2002.
2. Gilbert S, Loranger A and Marceau N: Keratins modulate c-Flip/extracellular signal-regulated kinase 1 and 2 antiapoptotic signaling in simple epithelial cells. Mol Cell Biol 24: 7072-7081, 2004. (Pubitemid 39014434)
3. Reichelt J, Furstenberger G and Magin TM: Loss of keratin 10 leads to mitogen-activated protein kinase (MAPK) activation, increased keratinocyte turnover, and decreased tumor formation in mice. Invest Dermatol 123: 973-981, 2004. (Pubitemid 39391945)
4. Ku NO and Omary MB: A disease- and phosphorylation-related nonmechanical function for keratin 8. J Cell Biol 174: 115-125, 2006.
5. Tao GZ, Toivola DM, Zhou O, Strnad P, Xu B, Michie SA and Omary MB: Protein phosphatase-2A associates with and dephosphorylates keratin 8 after hyposmotic stress in a site- and cell-specific manner. J Cell Sci 119: 1425-1432, 2006. (Pubitemid 43756558)
6. 1/S transition. Exp Cell Res 313: 179-194, 2007.
7. Lam KY, Lui MC and Lo CY: Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 27: 631-635, 2001. (Pubitemid 33062169)
8. Chu YW, Runyan RB, Oshima RG and Hendrix MJC: Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 90: 4261-4265, 1993. (Pubitemid 23134206)
9. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY and Xia QC: From proteomic analysis to clinical significance. Overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 3: 73-81, 2004.
10. Beesley MF and McLaren KM: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 41: 236-243, 2002.
11. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH and Nam SJ: Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1 and E-cadherin in thyroid carcinomas. J Korean Med Sci 20: 853-859, 2005. (Pubitemid 41587245)
12. Cerilli LA, Mills SE, Rumpel CA, Dudley TH and Moskaluk CA: Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol 118: 186-193, 2002. (Pubitemid 46068996)
13. Nasser SM, Pitman MB, Pilch BZ and Faquin WC: Fine-needle aspiration biopsy of papillary thyroid carcinoma. Diagnostic utility of cytokeratin 19 immunostaining. Cancer Cytopathol 90: 307-312, 2000.
14. Khurana KK, Truong LD, LiVolsi VA and Baloch ZW: Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Arch Pathol Lab Med 127: 579-583, 2003.
15. Hirokawa M, Inagaki A, Kobayashi H, Kanahara T, Manabe T and Sonoo H: Expression of cytokeratin 19 in cytologic specimens of thyroid. Diagn Cytopathol 22: 197-198, 2000. (Pubitemid 30115313)
16. De Matos PS, Ferreira AP, De Oliveira Facuri F, Assumpção LVM, Metze K and Ward LS: Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47: 391-401, 2005. (Pubitemid 41428488)
17. Miettinen M, Kovatich AJ and Kärkkäinen P: Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Virchows Arch 431: 407-413, 1997.
18. Sahoo S, Hoda SA, Rosai J and DeLellis RA: Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 116: 696-702, 2001. (Pubitemid 34453210)
19. Prasad MJ, Pellegata NS, Huang Y, Nagaraja HN, De la Chapelle A and Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin 19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18: 48-57, 2005. (Pubitemid 40128094)
20. Fonseca E, Nesland JM, Höie J and Sobrinho-Simões M: Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch 430: 239-245, 1997. (Pubitemid 27151935)
21. Krzeslak A, Pomorski L, Gaj Z and Lipinska A: Differences in glycosylation of intracellular proteins between benign and malignant thyroid neoplasms. Cancer Lett 196: 101-107, 2003. (Pubitemid 36830917)
22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
23. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4355, 1979. (Pubitemid 9256559)
24. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurements with the Folin phenol reagent. J Biol Chem 193: 262-275, 1951.
25. Barak V, Goike H, Panaretakis KW and Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 37: 529-540, 2004. (Pubitemid 38845016)
26. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A and Kloos RT: Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45: 39-46, 2004. (Pubitemid 38969560)
27. Shin E, Chung WY, Yang WI, Park CS and Hong SW: RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation. J Korean Med Sci 20: 98-104, 2005. (Pubitemid 40342215)
28. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ and LiVolsi VA: Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 17: 225-234, 2006. (Pubitemid 46279670)